Anthony R. Mato, MD, MSCE

Articles

Lung Cancer and Leukemia Recap at ASCO 2021: Drs Ed Kim and Anthony Mato

June 6th 2021

OncLive sits down with Edward S. Kim, MD, and Anthony R. Mato, MD, on the pivotal studies in lung cancer and leukemia at the 2021 ASCO Annual Meeting.

Dr. Mato on the Efficacy of Fixed-Duration Venetoclax-Based Combo in CLL

April 8th 2020

Anthony R. Mato, MD, MSCE, discusses the phase III CLL14 trial, which evaluated the efficacy of fixed-duration treatment with venetoclax plus obinutuzumab in patients with chronic lymphocytic leukemia.

Dr. Mato on the CLL14 Trial Results in CLL

December 19th 2019

Anthony R. Mato, MD, MSCE, discusses the phase III CLL14 trial in patients with previously untreated chronic lymphocytic leukemia.

Dr. Mato on Ibrutinib Versus Acalabrutinib in CLL

November 23rd 2019

Anthony R. Mato, MD, MSCE, discusses differences between the use of ibrutinib (Imbruvica) and acalabrutinib (Calquence) in chronic lymphocytic leukemia (CLL).

Dr. Mato on Ibrutinib-Based Combinations in CLL

November 21st 2019

Anthony R. Mato, MD, MSCE, discusses ibrutinib-based combinations in chronic lymphocytic leukemia.

Dr. Mato on Rituximab Biosimilars in CLL

November 1st 2019

Anthony R. Mato, MD, MSCE, discusses the introduction of rituximab biosimilars in chronic lymphocytic leukemia.

Dr. Mato on Immunotherapy Options in CLL

October 22nd 2019

Anthony R. Mato, MD, MSCE, discusses the current immunotherapy options for patients with chronic lymphocytic leukemia.

Dr. Mato on the Use of Biosimilars in CLL

October 17th 2019

Anthony R. Mato, MD, MSCE, discusses the use of biosimilars in chronic lymphocytic leukemia.

Dr. Mato on Utilizing CAR T Cells in CLL

October 15th 2019

Anthony R. Mato, MD, MSCE, discusses where CAR T cell-therapy will fit into the treatment paradigm of chronic lymphocytic leukemia.